摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(3,4-dihydro-2H-chromen-2-ylmethyl)-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine

中文名称
——
中文别名
——
英文名称
N-(3,4-dihydro-2H-chromen-2-ylmethyl)-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine
英文别名
——
N-(3,4-dihydro-2H-chromen-2-ylmethyl)-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine化学式
CAS
——
化学式
C17H26N4O
mdl
——
分子量
302.4
InChiKey
QVSXOXCYXPQXMF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    22
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    57.7
  • 氢给体数:
    3
  • 氢受体数:
    3

文献信息

  • [EN] METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES<br/>[FR] PROCÉDÉS DE SYNTHÈSE DE CARBONATES DE N-HYDROXYSUCCINIMIDYLE
    申请人:XENOPORT INC
    公开号:WO2010017498A1
    公开(公告)日:2010-02-11
    The present disclosure relates to methods of synthesizing N-hydroxysuccinimidyl-carbonate intermediates from the corresponding sulfones useful in the preparation of 1-(acyloxy)-alkyl carbamate prodrugs.
    本公开涉及一种从相应砜合成N-羟基琥珀酰亚胺-碳酸酯中间体的方法,该中间体在制备1-(酰氧基)-烷基氨甲酸酯前药中有用。
  • [EN] POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS POLYMÉRIQUES HYPERBRANCHÉS
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013024048A1
    公开(公告)日:2013-02-21
    The present invention relates to water-soluble carrier-linked prodrugs of formula (I),wherein POL is a polymeric moiety,each Hyp is independently a hyperbranched moiety,each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water- soluble carrier-linked prodrugs and methods of treatment.
    本发明涉及水溶性载体连接的前药,其化学式为(I),其中POL是聚合物基团,每个Hyp是独立的超支化基团,每个基团SP是独立的间隔基团,每个L是独立的可逆前药连接基团,m为0或1,每个n是独立的整数,范围从2到200,每个x是独立的0或1。此外,还涉及包含所述水溶性载体连接的前药的药物组合物和治疗方法。
  • METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS
    申请人:XENOPORT, INC.
    公开号:US20140243544A1
    公开(公告)日:2014-08-28
    Methods of preparing carbamate prodrugs of amine-containing drugs are provided. Carbonates useful in the synthesis of the carbamate prodrugs are also provided.
    提供了制备胺类药物的氨基甲酸酯前药的方法。还提供了在合成氨基甲酸酯前药中有用的碳酸盐。
  • [EN] HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS HYDROSOLUBLES DE FORTE CHARGE
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013024047A1
    公开(公告)日:2013-02-21
    The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independendly a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use asmedicament or diagnostic, and methods of treatment.
    本发明涉及水溶性载体连接的前药,其化学式为(I),其中B、A和Hyp形成载体,B是一个分支核心,每个A独立地是一条聚乙二醇基聚合链,每个Hyp独立地是一个分支基团,每个SP独立地是一个间隔基团,每个L独立地是一个可逆前药连接基团,每个D独立地是一个生物活性基团,每个x独立地为0或1,每个m独立地是从2到64的整数,n是从3到32的整数;或其药学上可接受的盐。进一步涉及包括所述水溶性载体连接的前药的药物组合物,其用作药物或诊断,以及治疗方法。
  • 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof
    申请人:——
    公开号:US20040067962A1
    公开(公告)日:2004-04-08
    The present invention provides a compound of the formula (I), and the pharmaceutically acceptable salts and solvates thereof, which is useful for treating bladder over-activity or urinary incontinence.
    本发明提供了一种符合式(I)的化合物,以及其药用可接受的盐和溶剂合物,用于治疗膀胱过度活动或尿失禁。
查看更多